Thus, the aim of this review is to describe current knowledge of the pathophysiology of portal hypertension with focus on soluble guanylate (sGC) and PDE-5, enzymes whose activities finally regulate cGMP availability. The gene discussed is PDE5A; the disease is portal hypertension.